收费全文 | 17579篇 |
免费 | 1124篇 |
国内免费 | 103篇 |
耳鼻咽喉 | 258篇 |
儿科学 | 561篇 |
妇产科学 | 483篇 |
基础医学 | 1796篇 |
口腔科学 | 474篇 |
临床医学 | 1407篇 |
内科学 | 3769篇 |
皮肤病学 | 317篇 |
神经病学 | 896篇 |
特种医学 | 581篇 |
外国民族医学 | 2篇 |
外科学 | 3316篇 |
综合类 | 472篇 |
现状与发展 | 1篇 |
一般理论 | 21篇 |
预防医学 | 1153篇 |
眼科学 | 429篇 |
药学 | 1455篇 |
中国医学 | 123篇 |
肿瘤学 | 1292篇 |
2023年 | 167篇 |
2022年 | 434篇 |
2021年 | 852篇 |
2020年 | 455篇 |
2019年 | 572篇 |
2018年 | 709篇 |
2017年 | 439篇 |
2016年 | 551篇 |
2015年 | 613篇 |
2014年 | 799篇 |
2013年 | 934篇 |
2012年 | 1370篇 |
2011年 | 1389篇 |
2010年 | 818篇 |
2009年 | 622篇 |
2008年 | 984篇 |
2007年 | 1034篇 |
2006年 | 968篇 |
2005年 | 871篇 |
2004年 | 762篇 |
2003年 | 689篇 |
2002年 | 617篇 |
2001年 | 210篇 |
2000年 | 174篇 |
1999年 | 168篇 |
1998年 | 131篇 |
1997年 | 82篇 |
1996年 | 84篇 |
1995年 | 57篇 |
1994年 | 66篇 |
1993年 | 48篇 |
1992年 | 116篇 |
1991年 | 72篇 |
1990年 | 81篇 |
1989年 | 74篇 |
1988年 | 61篇 |
1987年 | 58篇 |
1986年 | 30篇 |
1985年 | 56篇 |
1984年 | 41篇 |
1983年 | 51篇 |
1982年 | 37篇 |
1980年 | 31篇 |
1979年 | 42篇 |
1978年 | 32篇 |
1977年 | 34篇 |
1976年 | 22篇 |
1974年 | 41篇 |
1973年 | 41篇 |
1972年 | 32篇 |
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献Material and methods: original research studies were searched from seven databases (MEDLINE, EMBASE, CENTRAL, CINAHL, SCOPUS, PEDro and PubMed). Subsequently, two independent reviewers screened the titles and abstracts followed by full-text reviews to assess the studies' eligibility.
Results: eleven studies met the inclusion criteria and had data abstracted and quality assessed. Methodology varied considerably and yet cognitive tasks resulted in the ΔO2Hb increasing in 8 of the 11 and ΔHHb decreasing in 8 of 8 studies that reported this outcome. The cognitive tasks from 10 of the 11 studies were classified as “Working Memory” and “Verbal Fluency Tasks”.
Conclusions: although, the data comparison was challenging provided the heterogeneity in methodology, the results across studies were similar. 相似文献